Guest Mohamad Mohty discusses updates on BCMA-targeting bispecific antibodies for multiple myeloma from EHA & ASCO 2024. Topics include MagnetisMM-3 trial data on elranatamab, real-world findings, step-up dosing of teclistamab, MAIC comparison of linvoseltamab with teclistamab, and sequencing of bispecific antibodies with CAR T-cells.

Experts Mohamad Mohty, Ernst Holler, and Florent Malard share insights on treating GvHD post stem cell transplant, discussing new therapies and the impact of the gut microbiome. Topics include novel agents like ruxolitinib, the role of antibiotics on gut health, benefits of FMT in refractory disorders, and the link between bacterial antigens and transplant outcomes.

Experts discuss the challenges of sequencing BCMA therapies in multiple myeloma, the prognostic value of circulating tumor cells, and the growing role of quadruplet therapies. They explore optimal combinations and sequencing, the Perseus trial comparing DARA VRD and VRD treatments, and the use of Dara KRD for newly diagnosed myeloma patients.